A clinical trial at Addenbrooke's Hospital, Cambridge is the first to explore using precision immunotherapies to treat pancreatic cancer, one of the hardest to treat forms of cancer. The trial will pilot a new system for running clinical trials in the UK intended to make them faster and more accessible for patients.
Precision medicine has transformed the treatment of many cancer's yet little has changed for people with pancreatic cancer. A new trial led by Dr Pippa Corrie, consultant medical oncologist at Addenbrooke's Hospital, aims to change this by being the first to trial a precision medicine immunotherapy approach in this challenging cancer.

Dr Pippa Corrie, consultant medical oncologist, PemOla Trial Lead
The trial is the first to pilot a new "Just in time" scheme run by the National Institute for Health and Care Research (NIHR), which could reduce the time needed for hospitals to join a clinical trial from months to only days. If successful, the scheme could allow more patients to benefit from clinical trials without the need to travel to specialist hospitals. The PemOla trial is funded by the Efficacy and Mechanism Evaluation (EME) Programme, a partnership between the NIHR and the Medical Research Council (MRC), and supported by MSD who are providing the study drug. The trial is being run from the Cambridge Clinical Trials Unit and sponsored by Cambridge University Hospitals NHS Foundation Trust.
For full article visit: CUH news
Cambridge researchers have discovered that an existing therapy which boosts protective immune cells in people who have recently had heart attacks reduces…
A drug mimicking the hormone progesterone has anti-cancer activity when used together with conventional anti-oestrogen treatment for women with breast…
An early-stage trial, recently opened at Addenbrooke's Hospital, offers new hope to people with late-stage pancreatic cancer and their families.
…